GlaxoKline partners with Gilead to commercialise Viread

November 29, 2009

ercialise_Viread

Posted on 25/11/2009 in Pharmacy Supplier News

GlaxoKline has revealed that it plans to work with Gilead to commercialise

Viread (tenofovir disoproxil fumarate), a drug for the treatment of chronic

hepatitis B (HBV) in adults.

The joint commercialisation efforts of the firms will increase access to the

drug to patients who have not yet used it.

As part of the new contract, Gilead will retain the rights to Viread in markets

such as Hong Kong, Singapore and Taiwan, while GlaxoKline will be

responsible for its registration and commercialisation in China.

" The agreement with Gilead to develop and launch Viread in China builds on [our]

strong heritage in hepatitis B and provides an important addition to

GlaxoKline's current portfolio in one of our key markets, " commented Abbas

Hussain, president of emerging markets at GlaxoKline.

November 29, 2009

ercialise_Viread

GlaxoKline partners with Gilead to commercialise Viread

Posted on 25/11/2009 in Pharmacy Supplier News

GlaxoKline has revealed that it plans to work with Gilead to commercialise

Viread (tenofovir disoproxil fumarate), a drug for the treatment of chronic

hepatitis B (HBV) in adults.

The joint commercialisation efforts of the firms will increase access to the

drug to patients who have not yet used it.

As part of the new contract, Gilead will retain the rights to Viread in markets

such as Hong Kong, Singapore and Taiwan, while GlaxoKline will be

responsible for its registration and commercialisation in China.

" The agreement with Gilead to develop and launch Viread in China builds on [our]

strong heritage in hepatitis B and provides an important addition to

GlaxoKline's current portfolio in one of our key markets, " commented Abbas

Hussain, president of emerging markets at GlaxoKline.

Recommended Posts